Opinion|Videos|February 10, 2025
Best Practices for Employers to Maximize Uptake of Biosimilars
Panelists discuss how employers optimize biosimilar uptake through strategic formulary design, financial incentives, and provider education, enabling health care systems to achieve substantial cost savings while maintaining high-quality patient care.
Episodes in this series
Video content above is prompted by the following:
- What are best practices for employers working with pharmacy benefit managers and health plans to ensure maximal uptake and cost savings of biosimilars?
- Please share how you were able to achieve this in practice.
Related to this article
Upper-extremity synovial sarcoma required more staged surgery, while lower-extremity disease carried more complications and metastases.
The National Comprehensive Cancer Network update on mantle cell lymphoma puts covalent BTK inhibitors, MRD testing, and TP53 sequencing at the center of frontline care, while adding pirtobrutinib and a pair of CAR T-cell therapies for disease that progresses on a BTK inhibitor.
CDC's David A. Siegel, MD, MPH, on rising cancer diagnoses, falling deaths, and where CDC's cancer control resources go next.
CDC's Jane Henley, MSPH, explains what's behind falling lung cancer deaths and why 4 in 5 eligible adults still aren't getting screened.
Machine learning identified age, BMI, income, and reproductive factors as key predictors of overactive bladder risk among US women.
Tammy Lundstrom, MD, JD, discusses the new childhood vaccine order, single-dose MMR access concerns, and the measles resurgence.
Twice-daily dosing of the oral JAK inhibitor deuruxolitinib nearly tripled response rates over once-daily dosing in severe alopecia areata.
Clinicians pair CD20×CD3 bispecifics with radiotherapy in relapsed B‑cell lymphoma, but data stay sparse—early safety signals prompt trials.
Trending on AJMC
1
NCCN Journal Publishes Guidelines Update in Mantle Cell Lymphoma
2
Health System Pharmacies Keep Patients on GLP-1 Therapy
3
Peptide Regulation Debate Intensifies After FDA Advisory Panel's Controversial Vote
4
Philadelphia Experts Share How Bispecific Delivery in Myeloma Varies by Site
5